Short Interest in Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB) Decreases By 91.3%

Posted by on May 28th, 2026

Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB – Get Free Report) saw a large decline in short interest during the month of May. As of May 15th, there was short interest totaling 387 shares, a decline of 91.3% from the April 30th total of 4,431 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily volume of 30,829 shares, the short-interest ratio is presently 0.0 days.

Matinas Biopharma Trading Up 12.3%

Shares of Matinas Biopharma stock traded up $0.09 during trading on Thursday, hitting $0.82. 45,319 shares of the stock were exchanged, compared to its average volume of 96,441. Matinas Biopharma has a 1-year low of $0.48 and a 1-year high of $3.09. The stock has a market capitalization of $5.26 million, a price-to-earnings ratio of -0.41 and a beta of 1.61. The company has a fifty day moving average price of $0.59 and a 200-day moving average price of $0.67.

Matinas Biopharma (NYSEAMERICAN:MTNB – Get Free Report) last announced its quarterly earnings results on Friday, May 8th. The company reported ($0.30) EPS for the quarter.

Institutional Trading of Matinas Biopharma

An institutional investor recently bought a new position in Matinas Biopharma stock. DRW Securities LLC purchased a new position in shares of Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned 0.72% of Matinas Biopharma at the end of the most recent quarter. 11.77% of the stock is currently owned by institutional investors and hedge funds.

About Matinas Biopharma

(Get Free Report)

Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.

The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.

Read More

Receive News & Ratings for Matinas Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.